Isotiorga

Isotretinoin, the active ingredient in Isotiorga, is a retinoid presented as an oral tablet for oral use. It is indicated for the treatment of severe recalcitrant nodular acne in patients who have not responded to conventional therapies.

GNH USA supplies Isotiorga as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Isotretinoin is a retinoid that targets severe acne by modulating sebaceous gland activity.

Severe recalcitrant nodular acne: reduces existing lesions and prevents formation of new nodules.

Isotiorga may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Dry skin: increased skin dryness and flaking. - Cheilitis: cracked or inflamed lips. - Elevated liver enzymes: mild transaminase rise. - Hypertriglyceridemia: increase in blood triglyceride levels.

Serious or Rare Side Effects: - Severe depression or suicidal thoughts: mood changes requiring immediate evaluation. - Pancreatitis: abdominal pain with elevated enzymes. - Birth defects: teratogenic effects if exposure occurs during pregnancy.

When prescribing Isotiorga, clinicians should observe several safety measures. - Pregnancy testing: confirm negative pregnancy test before initiation and use effective contraception throughout therapy. - Baseline labs: obtain liver function tests and lipid profile prior to treatment. - Monthly monitoring: repeat liver enzymes and triglycerides during therapy. - Vision changes: advise patients to report new visual disturbances promptly. - Avoid vitamin A supplements: concurrent high‑dose vitamin A may increase toxicity. - Store at ambient temperature: keep below 25°C in original container, protect from moisture and light.

Isotiorga can interact with other medicines, affecting its safety or efficacy.

Major Interactions (Avoid): - Tetracyclines: increased risk of intracranial hypertension. - Vitamin A derivatives (e.g., acitretin): additive teratogenic risk. - Systemic corticosteroids: may exacerbate mood disorders.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce efficacy, consider alternative non‑hormonal methods. - Anticoagulants (warfarin): possible alteration of INR, monitor coagulation. - Lipid‑lowering agents (e.g., fibrates): may enhance triglyceride rise.